Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma
The combination of avelumab and axitinib demonstrated long-term efficacy in heavily pretreated patients with TC and TB3. This finding underscores the meaningful impact of immune checkpoint inhibitors and antiangiogenesis drugs on the prognosis of this patient population.
Authors
- Nadia Cordua (ORCID: https://orcid.org/0009-0006-6968-270X)
- Tommaso Martino De Pas
- Benedetta Tinterri
- Fabio De Vincenzo (ORCID: https://orcid.org/0000-0002-1811-7050)
- Isabella Sala (ORCID: https://orcid.org/0000-0002-4404-4537)
- Paolo Andrea Zucali (ORCID: https://orcid.org/0000-0002-2274-1702)
- Matteo Perrino (ORCID: https://orcid.org/0000-0001-9864-8814)
- Laura Pala (ORCID: https://orcid.org/0000-0002-0111-9869)
- Fabio Conforti (ORCID: https://orcid.org/0000-0002-6233-0502)
- Marzia Bendoni
- Jacopo Canzian (ORCID: https://orcid.org/0009-0008-0883-0582)
- Armando Santoro (ORCID: https://orcid.org/0000-0003-1709-9492)
- Chiara Catania (ORCID: https://orcid.org/0009-0008-2926-4663)
- Giuseppe Giaccone (ORCID: https://orcid.org/0000-0002-7392-1965)
- Emily Governini
Institutions
- Humanitas University (IT)
- Cornell College (US)
- Cornell University (US)
- Humanitas Gavazzeni (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Cancer
- Published
- 2025-09-15
- DOI
- https://doi.org/10.1002/cncr.70092
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00